Comparative Pharmacology
Head-to-head clinical analysis: BIPHETAMINE 20 versus RITALIN LA.
Peer-Reviewed Evidence
Head-to-head clinical analysis: BIPHETAMINE 20 versus RITALIN LA.
BIPHETAMINE 20 vs RITALIN LA
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Biphetamine 20 is a fixed-dose combination of amphetamine and dextroamphetamine, which are non-catecholamine sympathomimetic amines that promote the release of dopamine and norepinephrine from presynaptic neurons, and inhibit their reuptake, thereby increasing synaptic concentrations of these neurotransmitters in the central nervous system.
Methylphenidate is a central nervous system stimulant that blocks the reuptake of norepinephrine and dopamine into presynaptic neurons, increasing their concentrations in the synaptic cleft.
10-20 mg orally once daily in the morning; may increase to 20 mg twice daily (morning and noon) if needed.
20-60 mg orally once daily in the morning; capsules may be swallowed whole or sprinkled on applesauce.
None Documented
None Documented
0.5–1.5 hours for the immediate-release component; terminal elimination half-life of the total amphetamine salts is approximately 10–13 hours in adults
Methylphenidate: 3–4 hours (racemic); d-enantiomer: 6–8 hours; clinical context: duration of action 8–12 hours due to extended-release formulation
Renal (90% as unchanged drug and metabolites, with approximately 30% unchanged); fecal (10%)
Renal (78–97% as metabolites, primarily ritalinic acid, with <1% unchanged); fecal <2%
Category C
Category C
Central Nervous System Stimulant
Central Nervous System Stimulant